Malignant pleural effusion, current and evolving approaches for its diagnosis and management.

Malignant pleural effusion is a common and debilitating complication of advanced malignant diseases. This problem seems to affect particularly those with lung and breast cancer, contributing to the poor quality of life. Approximately half of all patients with metastatic cancer develop a malignant pleural effusion at some point, which is likely to cause significant symptoms such as dyspnea and cough. Evacuation of the pleural fluid and prevention of its re-accumulation are the main goals of management. Optimal treatment is controversial and there is no universally standard approach. Intervention options range from observation in the case of asymptomatic effusions through simple thoracentesis to more invasive methods such as chemical and mechanical pleurodesis, pleur-X catheter drainage, pleuroperitoneal shunting, and pleurectomy. The best results are reported with thoracoscopy and talc insufflation, with an acceptable morbidity. Development of novel methods to control malignant pleural effusion should be a high priority in palliative care of cancer patients. This article reviews the current, as well as, novel approaches that show some promise for the future. The aim is to identify the proper approach for each individual patient.

[1]  F. Rodríguez‐Panadero,et al.  Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. , 1993, Chest.

[2]  J. Ruckdeschel Management of malignant pleural effusions. , 1995, Seminars in oncology.

[3]  V. Villena,et al.  Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. , 2003, Lung cancer.

[4]  A. Mariano,et al.  New approaches in the diagnostic procedure of malignant pleural effusions. , 2004, Oncology reports.

[5]  J. Woodring Recognition of pleural effusion on supine radiographs: how much fluid is required? , 1984, AJR. American journal of roentgenology.

[6]  A. Crnjac The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions. , 2004, Wiener klinische Wochenschrift.

[7]  D. Hicklin,et al.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Allred,et al.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. , 1993, Human pathology.

[9]  M. J. Schiff,et al.  Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. , 2000, Chest.

[10]  E. Neville,et al.  BTS guidelines for the management of malignant pleural effusions. , 2003, Thorax.

[11]  P. Goldstraw,et al.  Management of recurrent malignant pleural effusions. The complementary role of talc pleurodesis and pleuroperitoneal shunting , 1995, Cancer.

[12]  V. Indumathi,et al.  A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions , 2000, Respirology.

[13]  V. Foresti Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions. , 1995, Respiration; international review of thoracic diseases.

[14]  N. Sneige,et al.  Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma , 2003, Cancer.

[15]  J. Aparicio,et al.  Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 Cases , 1998, Respiration.

[16]  W. Hsu,et al.  Ultrasound-guided small-bore Elecath tube insertion for the rapid sclerotherapy of malignant pleural effusion. , 1998, Japanese journal of clinical oncology.

[17]  S. Sahn,et al.  Talc pleurodesis for the treatment of pneumothorax and pleural effusion. , 1994, Chest.

[18]  F. Rey,et al.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. , 1995, Chest.

[19]  P. Eng,et al.  Pleural changes in malignant pleural effusions: appearance on computed tomography. , 1994, Cleveland Clinic journal of medicine.

[20]  W. Parulekar,et al.  Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. , 2001, Chest.

[21]  R. Light,et al.  Comparing transforming growth factor‐β2, talc and bleomycin as pleurodesing agents in sheep , 2002, Respirology.

[22]  F. Rodríguez‐Panadero Malignant pleural diseases. , 2000, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[23]  A. Nana,et al.  The efficacy of doxycycline as a pleural sclerosing agent in malignant pleural effusion: A prospective study , 1996, Respirology.

[24]  S. Sahn,et al.  Carcinomatous involvement of the pleura: an analysis of 96 patients. , 1977, The American journal of medicine.

[25]  D. Marmé,et al.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.

[26]  J. Seidman,et al.  Clinical Experience With Tetracycline Pleurodesis of Malignant Pleural Effusions , 1987, Southern medical journal.

[27]  S. Sahn,et al.  State of the art. The pleura. , 1988, The American review of respiratory disease.

[28]  F. Gleeson,et al.  Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. , 1999, Chest.

[29]  P. Astoul,et al.  Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions , 1993, Cancer.

[30]  C. Feo,et al.  [The ideal length of hospital stay in the surgical treatment of colorectal cancer]. , 2002, Annali italiani di chirurgia.

[31]  V. Raptopoulos,et al.  Complications associated with thoracentesis. A prospective, randomized study comparing three different methods. , 1990, Archives of internal medicine.

[32]  M. Charbonneau,et al.  Thoracoscopy for the diagnosis of pleural disease. , 1991, Annals of internal medicine.

[33]  R. Perng,et al.  The role of fiberoptic bronchoscopy in evaluating the causes of pleural effusions. , 1989, Archives of internal medicine.

[34]  P. Moulder,et al.  Iodized talc pleurodesis for the treatment of pleural effusions. , 1992, The Journal of thoracic and cardiovascular surgery.

[35]  A. Yim Port-site recurrence following video-assisted thoracoscopic surgery , 1995, Surgical Endoscopy.

[36]  A. Cantó,et al.  Points to consider when choosing a biopsy method in cases of pleurisy of unknown origin. , 1983, Chest.

[37]  S J Mentzer,et al.  Malignant effusive disease of the pleura and pericardium. , 1997, Chest.

[38]  M. Votaw,et al.  Pleural effusion in multiple myeloma , 1979, Cancer.

[39]  P. Rubin,et al.  The management of pleural effusions and chylothorax in lymphoma. , 1965, Radiology.

[40]  A. Bernard,et al.  Early and late mortality after pleurodesis for malignant pleural effusion. , 2002, The Annals of thoracic surgery.

[41]  A. Dekker,et al.  Diagnostic value of DNA analysis in effusions by flow cytometry and image analysis. A prospective study on 102 patients as compared with cytologic examination. , 1991, American journal of clinical pathology.

[42]  R. Livingston,et al.  Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. , 1982, Chest.

[43]  C. Kardinal,et al.  Pleural effusion in breast carcinoma: Analysis of 122 cases , 1981, Cancer.

[44]  D. Tassinari,et al.  Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Valdés,et al.  The etiology of pleural effusions in an area with high incidence of tuberculosis. , 1996, Chest.

[46]  A. Chella,et al.  [Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis]. , 1994, Minerva chirurgica.

[47]  P. Goldstraw,et al.  The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[48]  S. Sahn,et al.  Management of malignant pleural effusions. , 2001, The European respiratory journal.

[49]  A. Ardizzoni,et al.  Intrapleural natural beta interferon in the treatment of malignant pleural effusions. , 1988, Oncology.

[50]  K. Kovitz,et al.  A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions , 1999, Cancer.

[51]  S. Sahn,et al.  Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. , 2004, Chest.

[52]  I. Silverberg Management of effusions. , 1970, Oncology.

[53]  J. Aparicio,et al.  Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. , 1997, The European respiratory journal.

[54]  D. Alberts,et al.  Bleomycin pharmacokinetics in man. II. Intracavitary administration. , 1979, Cancer chemotherapy and pharmacology.

[55]  A. Catania,et al.  Volume‐regulated Cl− channels in human pleural mesothelioma cells , 2004, FEBS letters.

[56]  Sahn Sa Pleural diagnostic techniques. , 1995 .

[57]  G. Hillerdal,et al.  The impact of pleurodesis in malignant effusion on respiratory function. , 1999, Respiratory medicine.

[58]  D. Nauffal,et al.  Effect of thoracentesis on pulmonary gas exchange. , 1983, Thorax.

[59]  V. Rusch,et al.  Pleurodesis using talc slurry. , 1994, Chest.

[60]  P. E. Cardoso,et al.  Thoracoscopy talc poudrage : a 15-year experience. , 2001, Chest.

[61]  J. Norum,et al.  Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. , 1997, Journal of chemotherapy.

[62]  A. DeMaria,et al.  Diagnostic, Prognostic and Therapeutic Implications , 1974 .

[63]  S. Sahn,et al.  Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. , 1997, Chest.

[64]  Y. Aelony Dry talc pleurodesis via chest tube. , 2003, Chest.

[65]  E. Wiley,et al.  Evaluation of breast cancer metastases in pleural effusions by molecular biology techniques , 2002, Diagnostic cytopathology.

[66]  W. Wilmanns,et al.  P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining. , 1999, Oncology reports.

[67]  A. Gaudichet,et al.  Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. , 1984, Chest.

[68]  R. Light Management of pleural effusions. , 2000, Journal of the Formosan Medical Association = Taiwan yi zhi.

[69]  E. Montserrat,et al.  Characteristics and prognostic value of pleural effusions in non-Hodgkin's lymphomas. , 1985, European journal of respiratory diseases.

[70]  S. Barni,et al.  Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2 , 2001, Oncology.

[71]  U. Prakash,et al.  Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. , 1985, Mayo Clinic proceedings.

[72]  J. Heffner,et al.  Multilevel likelihood ratios for identifying exudative pleural effusions(*). , 2002, Chest.

[73]  M. Bains,et al.  Indications for pleurectomy in malignant effusion , 1975, Cancer.

[74]  J. Alegre,et al.  Polymorphonuclear Elastase in the Early Diagnosis of Complicated Pyogenic Pleural Effusions , 2003, Respiration.

[75]  H. Ngan,et al.  Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer , 1999, Acta obstetricia et gynecologica Scandinavica.

[76]  P. Godley,et al.  Major hemorrhage following administration of intrapleural streptokinase. , 1984, Chest.

[77]  F. Hausheer,et al.  Diagnosis and treatment of malignant pleural effusion , 1985, Cancer and Metastasis Reviews.

[78]  M. Neri,et al.  Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. , 2003, Lung cancer.

[79]  T. L. Svendsen,et al.  Treatment of malignant pleural effusion with drainage, with and without instillation of talc. , 1984, European journal of respiratory diseases.

[80]  N. Barbetakis,et al.  Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer , 2004, World journal of surgical oncology.

[81]  D. Weissberg,et al.  Talc pleurodesis : experience with 360 patients , 1993 .

[82]  T. Daniel Diagnostic thoracoscopy for pleural disease. , 1993, The Annals of thoracic surgery.

[83]  K. Kesler,et al.  Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. , 1993, The Journal of thoracic and cardiovascular surgery.

[84]  J. Heffner,et al.  Clinical efficacy of doxycycline for pleurodesis. , 1994, Chest.

[85]  J. Herndon,et al.  Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. , 1998, Chest.

[86]  W. Fry,et al.  Parietal pleurectomy for malignant pleural effusion , 1995, Annals of Surgical Oncology.

[87]  R. Light Useful tests on the pleural fluid in the management of patients with pleural effusions. , 1999, Current opinion in pulmonary medicine.

[88]  F. Rodríguez‐Panadero Talc pleurodesis for treating malignant pleural effusions. , 1995, Chest.

[89]  J. M. Tura,et al.  Talc preparations used for pleurodesis vary markedly from one preparation to another. , 2001, Chest.

[90]  R. Light,et al.  Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. , 2000, Chest.

[91]  K. Takazawa,et al.  [Adult case of isolated noncompaction of left ventricular myocardium revealed at hospitalization for tuberculous pleuritis]. , 1999, Journal of cardiology.

[92]  D. Sugarbaker,et al.  Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. , 1992, AJR. American journal of roentgenology.

[93]  S. Sahn Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas , 1998, Thorax.

[94]  Y. Aelony,et al.  Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. , 1998, Chest.

[95]  P. Astoul,et al.  Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. , 1996, Chest.

[96]  E. Patz,et al.  Ambulatory sclerotherapy for malignant pleural effusions. , 1996, Radiology.

[97]  D. Thickett,et al.  Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[98]  I. Fentiman,et al.  Pleural effusion in breast cancer: A review of 105 cases , 1981, Cancer.

[99]  M. Orringer,et al.  Statement of the AATS/STS Joint Committee on Thoracoscopy and Video Assisted Thoracic Surgery. , 1992, Journal of Thoracic and Cardiovascular Surgery.

[100]  W. Johnston The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients , 1985, Cancer.

[101]  R. Loddenkemper Thoracoscopy--state of the art. , 1998, The European respiratory journal.

[102]  S. Sahn,et al.  Chemical Pleurodesis for Malignant Pleural Effusions , 1994, Annals of Internal Medicine.

[103]  H. Magnussen,et al.  Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  H. Bayram,et al.  Comparison of the Effectiveness of Some Pleural Sclerosing Agents Used for Control of Effusions in Malignant Pleural Mesothelioma: A Review of 117 Cases , 2000, Respiration.

[105]  R. Cerfolio,et al.  Video-assisted thoracoscopic surgery using single-lumen endotracheal tube anesthesia. , 2004, Chest.

[106]  T B Ferguson,et al.  The treatment of malignant pleural effusions , 1974, Cancer.

[107]  S. Sahn,et al.  Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. , 1988, Annals of internal medicine.

[108]  D. Skinner,et al.  Pleuro–peritoneal Shunting: Alternative Therapy for Pleural Effusions , 1988, Annals of surgery.

[109]  J. Heffner,et al.  Tetracycline pleurodesis. Adios, farewell, adieu. , 1992, Chest.

[110]  J. Beamis,et al.  Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. , 1994, Thorax.

[111]  E. Scalzetti,et al.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. , 2005, Chest.

[112]  Cytologic effects of photodynamic therapy in body fluids , 1996, Diagnostic cytopathology.